Zymeworks becomes the latest mesothelin dropout
The group cans ZW171 after “on-target, off-tumour toxicity”.
Nuvalent’s next battleground is HER2
NVL-330 features among the latest crop of industry projects newly into human trials.
Amgen packs up in Claudin6
Meanwhile, Torl BioTherapeutics appears to be catching up with BioNTech.
